del Greco F, Huang C M, Quintanilla A
J Cardiovasc Pharmacol. 1981;3 Suppl 2:S99-103.
Methyldopa was administered for an average of 3 years to 435 patients with essential hypertension who were included in this retrospective survey. In 73% of patients, methyldopa was added to prior diuretic therapy, and in 19%, methyldopa and a diuretic were started concurrently. The remaining patients (8%) started treatment with methyldopa alone. After the initiation of methyldopa administration, a diuretic and/or additional antihypertensive agent(s) was included in the treatment regimen of 167 (38%) of the 435 patients. Treatment was interrupted in 147 patients - 14 (3%) because of lack of response, 73 (17%) with adverse effects, and 60 (14%) because of other or unknown reasons. Two-thirds of the patients treated had been receiving methyldopa continuously up to the time these data were collected in early 1979.
在这项回顾性调查中,435例原发性高血压患者接受了平均3年的甲基多巴治疗。73%的患者在先前利尿剂治疗基础上加用甲基多巴,19%的患者甲基多巴与利尿剂同时起始治疗。其余患者(8%)单独开始使用甲基多巴治疗。开始使用甲基多巴治疗后,435例患者中有167例(38%)的治疗方案中加入了利尿剂和/或其他降压药物。147例患者中断治疗——14例(3%)因无反应,73例(17%)因不良反应,60例(14%)因其他或不明原因。截至1979年初收集这些数据时,三分之二接受治疗的患者一直在持续服用甲基多巴。